Obesity conveys poor outcome in patients with hepatocellular carcinoma treated by transarterial chemoembolization

详细信息    查看全文

• 作者：S.E. Wu^a ; H.W. Charles^a ; J.S. Park^b ; A.S. Goldenberg^c ; A.R. Deipolyi^a ; ^{adeipolyi@yahoo.com}
• 关键词：Obesity ; Hepatocellular carcinoma ; Transarterial chemoembolization ; Outcome ; Cancer treatment
• 刊名：Diagnostic and Interventional Imaging
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：98
• 期：1
• 页码：37-42
• 全文大小：694 K
• 卷排序：98

文摘

The purpose of this retrospective study was to evaluate the impact of obesity on radiologic outcomes in patients with hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE).Materials and methodsA total of 100 TACE procedures performed in 57 patients (42 men, 15 women) with a mean age of 62 years ± 8.4 (SD) (range: 39–83 years) were retrospectively reviewed. The 1–2-month follow-up computed tomography or magnetic resonance imaging examinations was assessed for new or residual disease and radiologic response using mRECIST criteria. Patients were categorized into two groups according to body mass index (BMI). Patients with BMI < 25 kg/m2 were further referred as to low BMI patients and those with BMI ≥ 25 kg/m2 as high BMI patients. Outcomes were compared between the two groups.ResultsLow and high BMI patients were similar in regard to age, gender, HCC etiology and stage, and pre-procedure disease burden. TACE for high BMI, compared to low BMI, patients resulted in lower complete response (39% vs. 66%) and higher progressive disease (21% vs. 5%) rates (P = 0.04), and higher rates of residual disease (63% vs. 39%, P = 0.02) and new lesions in untreated liver (39% vs. 18%, P = 0.04) on 1–2-month follow-up imaging.ConclusionsHigh BMI is associated with significantly more residual disease, new lesions, and progressive disease in patients with HCC treated by TACE.